title: Pharmacologic management of portal hypertension.
abstract: Progress in the knowledge of the pathophysiology of portal hypertension has disclosed new targets for therapy, resulting in a larger spectrum of drugs with a potential role for clinical practice. This review focuses on pharmacologic treatments already available for reducing portal pressure and summarizes drugs currently under investigation in this field.
authors.affiliation: Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic-IDIBAPS, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), University of Barcelona, c/Villarroel 170, Barcelona 08036, Spain.
authors.forename: Annalisa
authors.initials: A
authors.lastname: Berzigotti
authors.affiliation: Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic-IDIBAPS, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), University of Barcelona, c/Villarroel 170, Barcelona 08036, Spain. Electronic address: jbosch@clinic.ub.es.
authors.forename: Jaime
authors.initials: J
authors.lastname: Bosch
mesh_terms: D058668:Adrenergic alpha-1 Receptor Antagonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D002227:Carbazoles / Q000627:therapeutic use; D000077261:Carvedilol; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006975:Hypertension, Portal / Q000188:drug therapy* / Q000503:physiopathology; D008102:Liver Circulation / Q000187:drug effects; D008236:Lypressin / Q000031:analogs & derivatives / Q000627:therapeutic use; D017082:Portal Pressure / Q000187:drug effects; D011412:Propanolamines / Q000627:therapeutic use; D012084:Renin-Angiotensin System / Q000187:drug effects; D013004:Somatostatin / Q000031:analogs & derivatives / Q000627:therapeutic use; D013152:Splanchnic Circulation / Q000187:drug effects; D000077585:Terlipressin; D014655:Vascular Resistance / Q000187:drug effects; D014665:Vasodilator Agents / Q000627:therapeutic use
chemical_list: D058668:Adrenergic alpha-1 Receptor Antagonists; D000319:Adrenergic beta-Antagonists; D020533:Angiogenesis Inhibitors; D000900:Anti-Bacterial Agents; D000959:Antihypertensive Agents; D000975:Antioxidants; D002227:Carbazoles; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011412:Propanolamines; D014665:Vasodilator Agents; D000077261:Carvedilol; D008236:Lypressin; D013004:Somatostatin; D000077585:Terlipressin
keywords: Chronic liver disease; Drug therapy; Hepatic resistance; Portal pressure; Splanchnic blood flow